keyword
MENU ▼
Read by QxMD icon Read
search

Tiotropium

keyword
https://www.readbyqxmd.com/read/29910611/long-term-safety-of-tiotropium-olodaterol-respimat-%C3%A2-in-patients-with-moderate-to-very-severe-copd-and-renal-impairment-in-the-tonado-%C3%A2-studies
#1
Craig LaForce, Eric Derom, Ulrich Bothner, Isabel M Kloer, Matthias Trampisch, Roland Buhl
Introduction: The safety, lung function efficacy, and symptomatic benefits of combined tiotropium and olodaterol in patients with COPD were established in the 1-year TONADO® studies (NCT01431274; NCT01431287). As tiotropium is predominantly excreted by the kidneys, the long-term safety profile of tiotropium/olodaterol was investigated in patients with renal impairment in a prespecified safety analysis of the TONADO studies. Methods: These were 2 replicate, randomized, double-blind, parallel-group, 52-week Phase III studies that assessed tiotropium/olodaterol compared with tiotropium or olodaterol alone (all via Respimat® ) in patients with moderate-to-very severe COPD...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29907212/predicting-the-response-to-a-bronchodilator-in-patients-with-airflow-obstruction-and-lung-cancer
#2
Kazuhiro Ueda, Junichi Murakami, Toshiki Tanaka, Kumiko Yoshida, Taiga Kobayashi, Kimikazu Hamano
BACKGROUND: The aim of the present study was to clarify the predictors of the response of patients with resectable lung cancer and untreated airflow obstruction to tiotropium, an antimuscarinic bronchodilator. METHODS: Tiotropium was administered to 29 preoperative patients with untreated airflow obstruction. The forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1 ) were measured before and after the introduction of tiotropium. The response to tiotropium was determined based on the percentage gain in the FEV1 ...
August 2018: Journal of Surgical Research
https://www.readbyqxmd.com/read/29882826/a-muscarinic-antagonist-reduces-airway-inflammation-and-bronchoconstriction-induced-by-ambient-particulate-matter-in-a-mouse-model-of-asthma
#3
Jun Kurai, Masanari Watanabe, Hiroyuki Sano, Kyoko Iwata, Degejirihu Hantan, Eiji Shimizu
Ambient particulate matter (PM) can increase airway inflammation and induce bronchoconstriction in asthma. This study aimed to investigate the effect of tiotropium bromide, a long-acting muscarinic antagonist, on airway inflammation and bronchoconstriction induced by ambient PM in a mouse model of asthma. We compared the effect of tiotropium bromide to that of fluticasone propionate and formoterol fumarate. BALB/c mice were sensitized to ovalbumin (OVA) via the airways and then administered tiotropium bromide, fluticasone propionate, or formoterol fumarate...
June 6, 2018: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/29875845/comparison-of-effect-of-leukotriene-biosynthesis-blockers-and-inhibitors-of-phosphodiesterase-enzyme-in-patients-with-bronchial-hyperreactivity
#4
Naim Morina, Arsim Haliti, Ali Iljazi, Drita Islami, Sadi Bexheti, Adnan Bozalija, Hilmi Islami
AIM: Blocking effect of leukotriene biosynthesis-zileuton and blocking the effect of phosphodiesterase enzyme-diprophylline in the treatment of patients with bronchial asthma and bronchial increased reactivity, and tiotropium bromide as an antagonist of the muscarinic receptor studied in this work. METHODS: Parameters of the lung function are determined with Body plethysmography. The resistance of the airways (Raw) was registered and measured was intrathoracic gas volume (ITGV), and specific resistance (SRaw) was also calculated...
May 20, 2018: Open Access Macedonian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29872286/association-between-poor-therapy-adherence-to-inhaled-corticosteroids-and-tiotropium-and-morbidity-and-mortality-in-patients-with-copd
#5
Kirsten Koehorst-Ter Huurne, Catharina Gm Groothuis-Oudshoorn, Paul Dlpm vanderValk, Kris Ll Movig, Job van der Palen, Marjolein Brusse-Keizer
Aim: The aim of this study was to analyze the association between therapy adherence to inhaled corticosteroids (ICSs) and tiotropium on the one hand and morbidity and mortality in COPD on the other hand. Methods: Therapy adherence to ICSs and tiotropium over a 3-year period of, respectively, 635 and 505 patients was collected from pharmacy records. It was expressed as percentage and deemed optimal at ≥75-≤125%, suboptimal at ≥50%-<75%, and poor at <50% (underuse) or >125% (overuse)...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29869050/cost-effectiveness-of-pharmacological-treatments-for-asthma-a-systematic-review
#6
REVIEW
Carlos E Rodriguez-Martinez, Monica P Sossa-Briceño, Jose A Castro-Rodriguez
OBJECTIVE: The objective of this article was to summarize the findings of all the available studies on alternative pharmacological treatments for asthma and assess their methodological quality, as well as to identify the main drivers of the cost effectiveness of pharmacological treatments for the disease. METHODS: A systematic review of the literature in seven electronic databases was conducted in order to identify all the available health economic evidence on alternative pharmacological treatments for asthma published up to April 2017...
June 4, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29858004/rates-of-escalation-to-triple-copd-therapy-among-incident-users-of-lama-and-lama-laba
#7
Beth Hahn, Michael Hull, Cori Blauer-Peterson, Ami R Buikema, Riju Ray, Richard H Stanford
BACKGROUND: Improved outcomes have been reported for patients with chronic obstructive pulmonary disease (COPD) receiving combination long-acting muscarinic antagonist/long-acting β2 -agonist (LAMA/LABA) therapy compared with LAMA monotherapy. However, little is known about the relative characteristics of these patients and their rates of escalation to triple therapy (TT, combining a LAMA, LABA, and inhaled corticosteroid). This study aimed to characterize patients initiating treatment with the LAMA tiotropium (TIO) and the fixed-dose LAMA/LABA combination therapy umeclidinium/vilanterol (UMEC/VI), and to compare rates of escalation to TT between patients receiving these therapies...
June 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29851792/efficacy-of-budesonide-formoterol-and-tiotropium-combination-for-the-treatment-of-chinese-patients-with-chronic-obstructive-pulmonary-disease
#8
Jun-Fei Feng, Guo-Rong Ding, Yan-Zhong Xie, Dejun Zhao, Xuehui Wang
This study investigated the efficacy and safety of budesonide/formoterol (B/F) and tiotropium combination in the management of chronic obstructive pulmonary disease (COPD) in Chinese patients.Between January 2015 and November 2017, 113 eligible Chinese patients with COPD were included and divided into an intervention group and a control group. Sixty-three patients in the intervention group underwent B/F combined tiotropium, while 50 patients in the control group received tiotropium alone. The primary outcome was severity of dyspnea on exertion (DOE), measured by the 6-minute walk test (6MWT) scale...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29795478/comparison-of-glycopyrronium-versus-tiotropium-on-the-time-to-clinically-important-deteriorations-in-patients-with-copd-a-post-hoc-analysis-of-randomized-trials
#9
Anthony D'Urzo, Giovanni Bader, Steven Shen, Pankaj Goyal, Pablo Altman
Glycopyrronium is a once-daily, inhaled long-acting muscarinic antagonist (LAMA) demonstrating similar efficacy to inhaled tiotropium in patients with moderate-to-severe COPD; however, the benefit of LAMAs on COPD symptoms has been variable. COPD is a progressive disease in which many patients develop an acute or sustained deterioration. Data on the prevention of clinically important deteriorations (CID) using LAMAs are limited. A pooled analysis was performed on four Phase III trials (n = 2936) that compared the efficacy of glycopyrronium (n = 1859) with tiotropium (n = 1077)...
May 24, 2018: NPJ Primary Care Respiratory Medicine
https://www.readbyqxmd.com/read/29790581/the-pharmacokinetics-pharmacodynamics-and-tolerability-of-pur0200-a-novel-tiotropium-formulation-in-chronic-obstructive-pulmonary-disease
#10
Dave Singh, Arjun Ravi, Katie Kane, Tess Schmalbach, David L Hava
AIMS: PUR0200 is a tiotropium bromide formulation engineered with the iSPERSE dry powder delivery technology. PUR0200 is being developed as a bioequivalent alternative to tiotropium bromide delivered using Spiriva® HandiHaler® (HH). We investigated the bronchodilator effects, pharmacokinetics and safety of PUR0200 in COPD patients. METHODS: This was a randomised, placebo-controlled, crossover study with different PUR0200 doses and the comparator tiotropium HH...
May 23, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29785101/exacerbation-recovery-patterns-in-newly-diagnosed-or-maintenance-treatment-na%C3%A3-ve-patients-with-copd-secondary-analyses-of-ticari-1-trial-data
#11
David M Mannino, Emmanuelle M Clerisme-Beaty, Joanne Franceschina, Naitee Ting, Nancy K Leidy
Background: Little is known about the recovery patterns from acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in newly diagnosed or maintenance treatment-naïve patients with COPD. This study describes the course of AECOPD in these patients at the time of treatment for the symptoms of acute respiratory tract infection (RTI). Methods: This study was a secondary analysis of data from a 12-week, randomized clinical trial (TICARI 1) testing the efficacy and safety of once-daily tiotropium 18 µg maintenance therapy versus placebo in newly diagnosed or maintenance treatment-naïve COPD patients with acute RTI symptoms for ≤7 days...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29779416/long-term-triple-therapy-de-escalation-to-indacaterol-glycopyrronium-in-copd-patients-sunset-a-randomized-double-blind-triple-dummy-clinical-trial
#12
Kenneth R Chapman, John R Hurst, Stefan-Marian Frent, Michael Larbig, Robert Fogel, Tadhg Guerin, Donald Banerji, Francesco Patalano, Pankaj Goyal, Pascal Pfister, Konstantinos Kostikas, Jadwiga A Wedzicha
RATIONALE: There are no studies on ICS withdrawal in patients on long-term triple therapy in the absence of frequent exacerbations. OBJECTIVE: To evaluate the efficacy and safety of the direct de-escalation from long-term triple therapy to indacaterol/glycopyrronium in non-frequently exacerbating COPD patients. METHODS: This 26-week, randomized, double-blind, triple-dummy study assessed the direct change from long-term triple therapy to indacaterol/glycopyrronium (110/50μg once daily) or continuation of triple therapy (tiotropium 18μg once daily plus combination of salmeterol/fluticasone propionate [50/500μg] twice daily) in non-frequently exacerbating patients with moderate-to-severe COPD...
May 20, 2018: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29773969/cost-effectiveness-of-umeclidinium-compared-with-tiotropium-and-glycopyrronium-as-monotherapy-for-chronic-obstructive-pulmonary-disease-a-uk-perspective
#13
Dhvani Shah, Maurice Driessen, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs, Afisi S Ismaila
Background: Cost-effectiveness of once-daily umeclidinium bromide (UMEC) was compared with once-daily tiotropium (TIO) and once-daily glycopyrronium (GLY) in patients with chronic obstructive pulmonary disease (COPD) from a UK National Health Service (NHS) perspective. Methods: A linked-equation model was implemented to estimate COPD progression, associated healthcare costs, exacerbations rates, life years (LY) and quality-adjusted LY (QALYs). Statistical risk equations for endpoints and resource use were derived from the ECLIPSE and TORCH studies, respectively...
2018: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/29765214/tiotropium-inhibits-methacholine-induced-extracellular-matrix-production-via-%C3%AE-catenin-signaling-in-human-airway-smooth-muscle-cells
#14
Yating Huo, Lili Guan, Jiawen Xu, Luqian Zhou, Rongchang Chen
Background: Airway remodeling is an important feature of chronic obstructive pulmonary disease (COPD) that is associated with disease severity and irreversible airflow limitation. An extensive alteration of the extracellular matrix (ECM) surrounding the airway smooth muscle (ASM) bundle is one of the pathological manifestations of airway remodeling, which contributes to the decline in lung function. Tiotropium, a long-acting inhaled muscarinic receptor antagonist, has been confirmed to play a role in preventing airway remodeling including ECM deposition beyond bronchodilation in vivo, but the relationship between ASM cell (ASMC) relaxation and ECM production remains unclear...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29751157/tiotropium-add-on-therapy-improves-lung-function-in-children-with-symptomatic-moderate-asthma
#15
Christian Vogelberg, Michael Engel, István Laki, Jonathan A Bernstein, Olaf Schmidt, Georges El Azzi, Petra Moroni-Zentgraf, Ralf Sigmund, Eckard Hamelmann
No abstract text is available yet for this article.
May 8, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29750142/single-inhaler-triple-therapy-in-symptomatic-copd-patients-fulfil-subgroup-analyses
#16
David M G Halpin, Ruby Birk, Noushin Brealey, Gerard J Criner, Mark T Dransfield, Emma Hilton, David A Lomas, Chang-Qing Zhu, David A Lipson
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2 -agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled therapy for COPD, based on distinct patient clinical profiles, are unclear. FULFIL, a phase III, randomised, double-blind study, compared 24 weeks of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62...
April 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29750027/efficacy-of-tiotropium-olodaterol-on-lung-volume-exercise-capacity-and-physical-activity
#17
Masakazu Ichinose, Yoshiaki Minakata, Takashi Motegi, Jun Ueki, Yasuhiro Gon, Tetsuo Seki, Tatsuhiko Anzai, Shuhei Nakamura, Kazuto Hirata
Purpose: This study evaluated the efficacy of tiotropium/olodaterol vs tiotropium on lung function, exercise capacity, and physical activity in patients with COPD. Patients and methods: A total of 184 patients aged ≥40 years with COPD (Global Initiative for Chronic Obstructive Lung Disease stage II-IV) received tiotropium/olodaterol for 6 weeks, then tiotropium for 6 weeks, or vice versa. The primary endpoint was inspiratory capacity (IC) at peak post-dose. Results: Adjusted mean IC after 6-week treatment was 1...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29733738/case-study-a-combination-of-mepolizumab-and-omaluzimab-injections-for-severe-asthma
#18
Rejmon Dedaj, Lindie Unsel
A Combination of Mepolizumab and Omaluzimab injections for severe asthma. INTRODUCTION: Patients with severe persistent asthma account for a large proportion of asthma morbidity and health care expenditures. In this case report we describe the use of a combination of omalizumab and mepolizumab in severe asthma with elevated IgE levels and eosinophilic phenotype. CASE STUDY: We are treating a 55 year old woman with severe persistent eosinophilic asthma and elevated IgE levels...
May 7, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29731051/a-70-year-old-woman-with-a-prosthetic-mitral-valve-and-sudden-chest-pain
#19
María José Romero-Castro, Tania Seoane-García, Marinela Chaparro-Muñoz, Rafael García-Borbolla, Juan C García-Rubira
A 70-year-old woman presented to the ED with oppressive ongoing chest pain that had lasted for 1 hour and was accompanied by intense sweating. The patient had a previous history of bronchial asthma, severe degenerative mitral regurgitation, and an ostium secundum atrial septal defect that had been treated 6 years ago with a prosthetic mechanical mitral valve, Bicarbon 25, and an atrial septal defect closure. She was being treated with ciclesonide, tiotropium bromide, olodaterol, theophylline, and warfarin, adjusted according to the international normalized ratio...
May 2018: Chest
https://www.readbyqxmd.com/read/29719385/treatment-of-exacerbations-as-a-predictor-of-subsequent-outcomes-in-patients-with-copd
#20
Peter Ma Calverley, Antonio R Anzueto, Daniel Dusser, Achim Mueller, Norbert Metzdorf, Robert A Wise
Rationale: Exacerbations of COPD are managed differently, but whether treatment of one exacerbation predicts the likelihood of subsequent events is unknown. Objective: We examined whether the treatment given for exacerbations predicted subsequent outcomes. Methods: This was a post-hoc analysis of 17,135 patients with COPD from TIOtropium Safety and Performance In Respimat® (TIOSPIR® ). Patients treated with tiotropium with one or more moderate to severe exacerbations on study were analyzed using descriptive statistics, logistic and Cox regression analysis, and Kaplan-Meier plots...
2018: International Journal of Chronic Obstructive Pulmonary Disease
keyword
keyword
8894
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"